Biotech Values

[turtlepower]

Looks like AF has changed his mind about pereira since he wrote the following:

I'm the first one to say not to trust everything said by the CEO of a drug or biotech company. There are countless examples of investors led down the wrong path by management exaggerations or misstatements.
But in this case, I find it hard not to side with Pereira in the ferumoxytol argument. It's not that Berens doesn't present some good arguments. He does, and handicapping an FDA decision these days, especially one that seems to hinge on safety, is fraught with risk.

But when you speak with Pereira, or witness him answer questions about ferumoxytol in an investor meeting, he comes across as highly credible and assured. Moreover, this is not a guy learning the ins and outs of kidney disease and anemia on the job. Pereira is a highly trained physician and noted expert on kidney disease. He's a past president of the National Kidney Foundation and, literally, helped put together one of the seminal textbooks in the field.

So, in the Berens vs. Pereira fight, the edge, at least in my book, goes to Pereira.

http://www.thestreet.com/story/10411998/2/amags-iron-drug-put-to-the-fire.html